[Source: Journal of Medical Virology, full page: (LINK). Abstract, edited.]
The Outcome of COVID‐19 in Patients with Hematological Malignancy
Tugce Nur Yigenoglu MD, Naim Ata Associated Professor, Fevzi Altuntas Professor, Semih Bascı MD, Mehmet Sinan Dal Associated Professor, Serdal Korkmaz Associated Professor, Sinem Namdaroglu Associated Professor, Abdulkadir Basturk Associated Professor, Tuba Hacıbekiroglu Associated Professor, Mehmet Hilmi Dogu Associated Professor, İlhami Berber Associated Professor, Kursat Dal Associated Professor, Mehmet Ali Erkurt Professor, Burhan Turgut Professor, Mahir Ilgu, Osman Celik MD, Ersan Imrat, Suayip Birinci MD
First published: 10 August 2020 | DOI: https://doi.org/10.1002/jmv.26404
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/jmv.26404
In this study, we aim to report the outcome of COVID‐19 in patients with hematological malignancy in Turkey.
The data of laboratory‐confirmed 188,897 COVID‐19 patients diagnosed between March 11, 2020 and June 22, 2020 included in the Republic of Turkey, Ministry of Health database were analyzed retrospectively. All of the COVID‐19 patients with hematological malignancy (n=740) were included in the study and an age, gender and comorbidity matched COVID‐19 patients without cancer (n=740) at 1:1 ratio was used for comparison.
Non Hodgkin lymphoma (30.1%), myelodysplastic syndrome (19.7%), myeloproliferative neoplasm (15.7%), were the most common hematological malignancies. The rates of severe and critical disease were significantly higher in patients with hematological malignancy compared to the patients without cancer (p=0.001). The rates of hospital and intensive care unit (ICU) admission were higher in patients with hematological malignancy compared to the patients without cancer (p=0.023, p=0.001, respectively). The length of hospital stay and ICU stay were similar between groups (p=0.7, p=0.3; retrospectively). The rate of mechanical ventilation (MV) support was higher in patients with hematological malignancy compared to the control group (p=0.001). The case fatality rate (CFR) was 13.8% in patients with hematological malignancy, and it was 6.8% in the control group (p=0.001).
This study reveals that there is an increased risk of COVID‐19 related serious events (ICU admission, MV support or death) in patients with hematological malignancy compared to COVID‐19 patients without cancer and supports high vulnerability of patients with hematological malignancy in the current pandemic.
This article is protected by copyright. All rights reserved.
Keywords: SARS-CoV-2; COVID-19; Cancer; Hematology.